Non-Current Liabilities
Long-Term Debt
Pfizer Long-Term Debt decreased by 1.7% to $60.57B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 5.1%, from $57.64B to $60.57B. Over 5 years (FY 2020 to FY 2025), Long-Term Debt shows an upward trend with a 10.7% CAGR.
Analysis
StatementBalance Sheet Statement
SectionNon-Current Liabilities
CategoryLeverage
SignalContext dependent
VolatilityStable
First reportedQ4 2014
Last reportedQ1 2026
How to read this metric
An increase indicates higher financial leverage, which can amplify returns on equity but also increases interest expense and financial risk.
Detailed definition
Loans and financial obligations with a maturity period exceeding one year, typically consisting of corporate bonds and n...
Peer comparison
Capital-intensive firms or those with aggressive share buyback programs often carry higher long-term debt than asset-light competitors.
Metric ID:
long_term_debtHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $35.35B | $36.25B | $36.20B | $35.66B | $34.29B | $32.63B | $32.88B | $31.70B | $61.36B | $61.05B | $61.54B | $61.31B | $57.51B | $58.00B | $57.41B | $57.64B | $57.50B | $57.41B | $61.64B | $60.57B |
| QoQ Change | — | +2.5% | -0.2% | -1.5% | -3.8% | -4.9% | +0.8% | -3.6% | +93.5% | -0.5% | +0.8% | -0.4% | -6.2% | +0.9% | -1.0% | +0.4% | -0.2% | -0.2% | +7.4% | -1.7% |
| YoY Change | — | — | — | — | -3.0% | -10.0% | -9.1% | -11.1% | +78.9% | +87.1% | +87.1% | +93.4% | -6.3% | -5.0% | -6.7% | -6.0% | -0.0% | -1.0% | +7.4% | +5.1% |
Range$31.70B – $61.64B
CAGR+12.0%
Avg YoY Growth+18.8%
Median YoY Growth-2.0%
Long-Term Debt at Other Companies
Frequently Asked Questions
- What is Pfizer's long-term debt?
- Pfizer (PFE) reported long-term debt of $60.57B in Q1 2026.
- How has Pfizer's long-term debt changed year-over-year?
- Pfizer's long-term debt increased by 5.1% year-over-year, from $57.64B to $60.57B.
- What is the long-term trend for Pfizer's long-term debt?
- Over 5 years (2020 to 2025), Pfizer's long-term debt has grown at a 10.7% compound annual growth rate (CAGR), from $37.13B to $61.64B.
- What does long-term debt mean?
- Money the company has borrowed that doesn't need to be paid back for at least a year.